PMID- 16911680
OWN - NLM
STAT- MEDLINE
DCOM- 20070524
LR  - 20161124
IS  - 0815-9319 (Print)
IS  - 0815-9319 (Linking)
VI  - 21
IP  - 9
DP  - 2006 Sep
TI  - Comparison of the efficacy of rabeprazole 10 mg and omeprazole 20 mg for the 
      healing rapidity of peptic ulcer diseases.
PG  - 1381-7
AB  - AIM: Rabeprazole has been known to inhibit H(+)/K(+)-ATPase more rapidly than 
      omeprazole, the prototype proton pump inhibitor (PPI). The aim of this study was 
      to demonstrate equivalence between low-dose rabeprazole 10 mg and omeprazole 20 
      mg for the healing rapidity of active peptic ulcer and for improvement of 
      symptoms. Also, the effect of CYP2C19 genotypes on ulcer healing rapidity was 
      investigated. METHODS: A total of 112 patients with active peptic ulcer were 
      randomized to receive either rabeprazole 10 mg q.d. or omeprazole 20 mg q.d. for 
      6 weeks. The remaining ratios (%) and complete healing of the ulcer were 
      determined by endoscopy at 1 week and 6 weeks of treatment. The severity of ulcer 
      pain was also investigated during treatment. CYP2C19 genotype was determined by 
      the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) 
      method. RESULTS: The remaining ratio of peptic ulcers after 1 week and the 
      complete healing rate after 6 weeks in the rabeprazole versus omeprazole group 
      were 45.5% versus 50.3% (P = 0.475) and 80.6% versus 87.0% (P = 0.423), 
      respectively. CYP2C19 genotypes had no effect on the remaining ratio of peptic 
      ulcers after 1 week and the healing rate of peptic ulcers after 6 weeks in both 
      groups. The proportions of patients with symptom improvement or resolution were 
      comparable between the two groups. CONCLUSION: Low-dose rabeprazole 10 mg has a 
      similar efficacy for the healing rapidity of active peptic ulcer disease and 
      symptom improvement compared with standard-dose omeprazole 20 mg.
FAU - Ji, Sangwon
AU  - Ji S
AD  - Department of Internal Medicine, Yonsei University Wonju College of Medicine, 
      Wonju, South Korea.
FAU - Kim, Hyun Soo
AU  - Kim HS
FAU - Kim, Jae Woo
AU  - Kim JW
FAU - Jee, Myeong Kwan
AU  - Jee MK
FAU - Park, Kwang Wha
AU  - Park KW
FAU - Uh, Young
AU  - Uh Y
FAU - Lee, Dong Ki
AU  - Lee DK
FAU - Song, Jae Suk
AU  - Song JS
FAU - Baik, Soon Koo
AU  - Baik SK
FAU - Kwon, Sang Ok
AU  - Kwon SO
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - Australia
TA  - J Gastroenterol Hepatol
JT  - Journal of gastroenterology and hepatology
JID - 8607909
RN  - 0 (2-Pyridinylmethylsulfinylbenzimidazoles)
RN  - 0 (Anti-Ulcer Agents)
RN  - 0 (Enzyme Inhibitors)
RN  - 32828355LL (Rabeprazole)
RN  - EC 1.- (Mixed Function Oxygenases)
RN  - EC 1.14.14.1 (Aryl Hydrocarbon Hydroxylases)
RN  - EC 1.14.14.1 (CYP2C19 protein, human)
RN  - EC 1.14.14.1 (Cytochrome P-450 CYP2C19)
RN  - KG60484QX9 (Omeprazole)
SB  - IM
MH  - 2-Pyridinylmethylsulfinylbenzimidazoles/*therapeutic use
MH  - Adult
MH  - Anti-Ulcer Agents/*therapeutic use
MH  - Aryl Hydrocarbon Hydroxylases/metabolism
MH  - Cytochrome P-450 CYP2C19
MH  - Enzyme Inhibitors/*therapeutic use
MH  - Female
MH  - Genotype
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Mixed Function Oxygenases/metabolism
MH  - Omeprazole/*therapeutic use
MH  - Peptic Ulcer/*drug therapy
MH  - Polymorphism, Genetic
MH  - Rabeprazole
MH  - Treatment Outcome
EDAT- 2006/08/17 09:00
MHDA- 2007/05/26 09:00
CRDT- 2006/08/17 09:00
PHST- 2006/08/17 09:00 [pubmed]
PHST- 2007/05/26 09:00 [medline]
PHST- 2006/08/17 09:00 [entrez]
AID - JGH4314 [pii]
AID - 10.1111/j.1440-1746.2006.04314.x [doi]
PST - ppublish
SO  - J Gastroenterol Hepatol. 2006 Sep;21(9):1381-7. doi: 
      10.1111/j.1440-1746.2006.04314.x.